GRAIL Stock Tumbles - National Health Service Galleri Trial To Blame
GRAIL Inc. (NASDAQ:GRAL) shares are down during Monday's premarket session following the release of results from the NHS-Galleri trial, which evaluated the effectiveness of the Galleri test in reducing late-stage cancer diagnoses.
NHS-Galleri Trial Results
The NHS-Galleri trial results showed a favorable trend in reducing Stage IV cancer diagnoses, although the primary endpoint was not met. On Friday, GRAIL stock closed almost 51% lower.
The trial evaluated annual multi-cancer screening with the Galleri test in England's National Health Service (NHS) over three years, involving 142,000 participants aged 50 to 77.
The results indicated a clinically meaningful reduction in Stage IV diagnoses across a group of 12 deadly cancers, with a more than 20% reduction observed in subsequent screening rounds.
The broader market experienced declines on the previous trading day, with the Russell 2000 down 0.72% and the S&P 500 falling 0.50%.
GRAIL's decline occurred while the broader market was under pressure, suggesting that the stock's movement is primarily driven by company-specific news rather than overall market trends.
GRAIL's Technical Indicators Highlight Weakness
The stock is currently trading 47.3% below its 20-day simple moving average (SMA) and 40.5% below its 100-day SMA, indicating significant short-term weakness. Shares have increased by 112.58% over the past 12 months and are currently positioned closer to their 52-week lows than highs.
The RSI is at 50.93, which is considered neutral territory, while the MACD is at 0.2738, below its signal line at 0.5506, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.
- Key Resistance: $52.50
- Key Support: $20.50
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $100.50. Recent analyst moves include:
- Canaccord Genuity: Buy (Lowers Target to $80.00) (Feb. 20)
- Baird: Outperform (Lowers Target to $82.00) (Feb. 20)
GRAL Price Action: Grail shares were down 2.27% at $49.07 during premarket trading on Monday.
Photo by Wirestock Creators via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The Great Debate on AI Bottlenecks: 2027 Peak Bottleneck vs 2028 Capacity Boom and Price Collapse
Analyst Ben Bajarin believes that the demand for AI computing power will continue to grow, and 2027 will be the "bottleneck" year with the most severe industry-wide supply constraints. In 2028, supply and demand are expected to remain slightly tight but balanced. Jay Goldberg, on the other hand, warns that the historical cycle's iron law suggests that massive production capacity from companies like TSMC could lead to a collapse in pricing power and a reversion of profit margins to the mean. Both agree that the era of "blindly buying into the AI supply chain and seeing instant surges" has ended, and investors must now carefully select core assets with resilience in cross-cycle pricing.
Japan Is Dragging the World Down
Japan's government bond yields have surpassed 3% for the first time in 30 years, triggering global alarm. Nomura states that the epicenter of this global rise in long-term interest rates is within Japan itself—driven by uncontrolled fiscal expansion and expectations of central bank rate hikes, making fiscal risk premiums the main driving force. What’s more concerning to the market is that the continuous rise in Japanese bond yields not only threatens the balance sheets of global financial institutions, but may also burst the AI tech stock bubble and trigger a sudden economic slowdown.
Australian Dollar weakens to near 0.7200 as traders await US PPI inflation data
Crypto prices
More
